Differential gene expression profiling of cultured neu-transformed versus spontaneously-transformed rat cholangiocytes and of corresponding cholangiocarcinomas.
Previously, we described an orthotopic cholangiocarcinoma model based on bile duct inoculation of spontaneously-transformed low grade malignant rat BDE1 cholangiocytes (BDEsp cells) compared to high grade malignant erbB-2/neu- transformed BDE1 cholangiocytes (BDEneu cells) into the livers of syngeneic rats, which closely mimics clinical features of early versus advanced stages of the human cancer. We now used gene expression microarray together with quantitative real-time RT-PCR to profile genes differentially expressed in highly tumorigenic BDEneu cells and corresponding tumors compared to less aggressive tumorigenic BDEsp cells and tumors. Genes identified as being commonly overexpressed in parent BDEneu cells, tumors, and in a BDEneu tumor-derived cholangiocarcinoma cell line included Sox17, Krt20, Erbb2, and Sphk1 when respectively compared to BDEsp cells, tumors, and tumor-derived BDEsp cholangiocarcinoma cells. Muc1 was also prominently overexpressed in BDEneu cells and tumor-derived cholangiocarcinoma cells over that expressed in corresponding BDEsp cell lines. Periostin and tenascin-C, which were produced exclusively by cholangiocarcinoma-associated fibroblastic cells, were each significantly overexpressed in BDEneu tumors compared to BDEsp tumors. Interestingly, amphiregulin was representative of a gene found to be significantly underexpressed in vitro in BDEneu cells compared to BDEsp cells, but significantly overexpressed in BDEneu tumors compared to BDEsp tumors, and correlated with BDEneu cholangiocarcinoma progression in vivo. Our data support a unique animal model that recapitulates important molecular features of human cholangiocarcinoma progression, and may serve as a potentially powerful preclinical platform for identifying and rapidly testing novel molecular targeting strategies for cholangiocarcinoma therapy and/or prevention.
Dumur
Catherine I
CI
Department of Pathology, Division of Cellular and Molecular Pathogenesis, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0297, USA.
Campbell
Deanna J W
DJ
DeWitt
Jennifer L
JL
Oyesanya
Regina A
RA
Sirica
Alphonse E
AE
D000818:Animals; D001650:Bile Duct Neoplasms / Q000235:genetics* / Q000473:pathology; D001653:Bile Ducts, Intrahepatic / Q000473:pathology*; D015153:Blotting, Western; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D018281:Cholangiocarcinoma / Q000235:genetics* / Q000473:pathology; D016000:Cluster Analysis; D004195:Disease Models, Animal; D020869:Gene Expression Profiling; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D051381:Rats; D018719:Erb-b2 Receptor Tyrosine Kinases; D020133:Reverse Transcriptase Polymerase Chain Reaction
D018719:Erb-b2 Receptor Tyrosine Kinases
Hepatology. 2008 Apr;47(4):1178-90
18081149
J Hepatol. 1998 Oct;29(4):628-33
9824272
Mod Pathol. 2003 Oct;16(10):1019-27
14559985
Dig Liver Dis. 2005 Apr;37(4):269-74
15788211
Gastroenterology. 2005 Dec;129(6):2047-57
16344070
Int J Oncol. 2010 Feb;36(2):415-20
20043076
Clin Gastroenterol Hepatol. 2009 Nov;7(11 Suppl):S68-78
19896103
Hepatology. 2010 Sep;52(3):975-86
20607690
Methods. 2001 Dec;25(4):402-8
11846609
Am J Pathol. 2006 Apr;168(4):1155-68
16565491
Clin Chem. 2004 Nov;50(11):1994-2002
15364885
Dev Cell. 2009 Jul;17(1):62-74
19619492
Nucleic Acids Res. 2003 Feb 15;31(4):e15
12582260
Cancer Res. 2010 Mar 1;70(5):1960-9
20160031
Exp Mol Pathol. 2010 Dec;89(3):248-59
20655306
Hum Pathol. 2008 May;39(5):710-9
18329694
Oncol Rep. 2009 Sep;22(3):649-57
19639217
Biochem Biophys Res Commun. 2010 Jan 1;391(1):357-63
19913509
Mol Cancer. 2010 Jan 24;9:13
20096135
Eur J Cancer. 2009 Jan;45(1):33-47
18938071
Hepatology. 2009 Dec;50(6):1861-70
19821497
Am J Pathol. 2003 Jul;163(1):217-29
12819026
Gastroenterology. 2009 Oct;137(4):1346-57
19549530
Biochem Biophys Res Commun. 2008 Jan 18;365(3):555-61
18023415